PVA TePla AG

  • WKN: 746100
  • ISIN: DE0007461006
  • Land: Deutschland

Nachricht vom 27.08.2021 | 16:11

PVA TePla Group receives major order from Siltronic AG

PVA TePla AG / Key word(s): Incoming Orders
PVA TePla Group receives major order from Siltronic AG

27-Aug-2021 / 16:11 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


PVA TePla Group receives major order from Siltronic AG

PVA Crystal Growing Systems GmbH, a 100% subsidiary of PVA TePla AG (ISIN DE0007461006), today received an order worth EUR 95 million from Siltronic AG to supply crystal growing systems for the production of silicon wafers for the semiconductor industry. The order is related to Siltronic AG's decision to build a second 300 mm fab in Singapore.

The order received today will have an effect on sales revenues and earnings for the PVA TePla Group in the years 2023 to 2025.

 

 


Information and Explanation of the Issuer to this News:

'For some time now, our PVA TePla Group has been experiencing a significant increase in demand for production systems from the semiconductor industry. Due to the growing digitisation in many areas of life and the increasing miniaturisation of semiconductor components, we also see a promising development for our company in the coming years. The order we have now received from our long-standing customer Siltronic, which is significantly expanding its semiconductor wafer production in Singapore as part of its recently announced investment, underlines this market trend,' says Manfred Bender, CEO of PVA TePla AG.

Oliver Höfer, COO at PVA TePla AG, adds: 'I am delighted that we are able to continue our partnership with Siltronic AG in this major project. Our unique expertise in the construction of highly complex production systems has been proven once again by this order.'

For further information, please contact:

Dr. Gert Fisahn
Investor Relations
Phone: +49(0)641/68690-400
gert.fisahn@pvatepla.com


 

27-Aug-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Vonovia SE: Vorstandsmitglieder von Vonovia werden ihre Bezugsrechte ausüben

30. November 2021, 16:02

Aktueller Webcast

HelloFresh SE

Capital Markets Day

08. Dezember 2021

Aktuelle Research-Studie

clearvise AG

Original-Research: clearvise AG (von First Berlin Equity Research GmbH): Buy

30. November 2021